Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?

2 Aug 2023

Abstract excerpt

Germline BRCA1/2 alterations in the Homologous Recombination (HR) pathway are considered as main susceptibility biomarkers to Hereditary Breast and Ovarian Cancers (HBOC). The modern molecular biology technologies allowed to characterize germline and somatic BRCA1/2 alterations in several malignancies, broadening the landscape of BRCA1/2 -alterated tumors. In the last years, BRCA genetic testing, beyond the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37536445
DOI: 10.1016/j.critrevonc.2023.104086

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?PMID 37536445Read ↗

Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid TumorsSemantic proximity Read ↗

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Semantic proximity Read ↗

Cancer treatment according to BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2Semantic proximity Read ↗

Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapySemantic proximity Read ↗

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and BeyondSemantic proximity Read ↗

New Therapeutic Options for BRCA Mutant PatientsSemantic proximity Read ↗

PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.Semantic proximity Read ↗

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition TestingSemantic proximity Read ↗

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read ↗

A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.Semantic proximity Read ↗

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.